Cotinga Pharmaceuticals Inc. (COTQF) Research

Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.

Market snapshot

Symbol
COTQF
Price
$0.00
Day change
0.00%
Market cap
$2.2K
P/E ratio
-0.00x
52-week range
0.0001-0.0001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Anthera Pharmaceuticals, Inc. (ANTH)
  • Dermisonics, Inc. (DMSI)
  • Fiore Cannabis Ltd. (FIORF)
  • ForU Holdings, Inc. (FORU)
  • iBX Group, Inc. (IBXG)
  • 9 Meters Biopharma, Inc. (NMTRQ)
  • Optigenex Inc. (OPGX)
  • OncoVista Innovative Therapies, Inc. (OVIT)

Open Cotinga Pharmaceuticals Inc. (COTQF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.